...
首页> 外文期刊>The American Journal of the Medical Sciences >Preoperative probiotics decrease postoperative infectious complications of colorectal cancer
【24h】

Preoperative probiotics decrease postoperative infectious complications of colorectal cancer

机译:术前益生菌减少大肠癌术后感染并发症

获取原文
获取原文并翻译 | 示例

摘要

Background: The objective is to elucidate the effects of oral bifid triple viable probiotics among patients with colorectal cancer. Methods: Sixty patients undergoing radical colorectal resection were randomly assigned to 3-day (days -5 to -3) preoperative probiotics (group A, n = 30) or placebo (group B, n = 30) treatment. The alteration of intestinal flora was evaluated by fecal cultures of Escherichia coli, Bifidobacterium longum and intestinal fungi; the gut barrier function by serum endotoxins and D-lactic acids and the immune and stress responses by peripheral blood immunoglobins, interleukin-6 and C-reactive protein. Postoperative infections were documented physically, radiologically and microbiologically. Results: Inverted Bifidobacterium/Escherichia ratios were preoperatively and postoperatively present in group B (both P < 0.05). Bifidobacterium counts increased significantly, whereas Escherichia counts decreased significantly on postoperative days 3 to 5 (P < 0.05), along with reversing the Bifidobacterium/Escherichia ratio inversion until postoperative days 3 to 5 in group A. Group A also had lower levels of endotoxins, D-lactic acids, serum interleukin-6 and C-reactive protein but higher levels of serum IgG and sIgA (all P < 0.05) than group B. The incidences of postoperative infectious complications were 3.3% to 6.7% and 3.3% to 30% in groups A and B (overall, 10.0% versus 33.3%, P < 0.05), respectively. Conclusion: The preoperative oral bifid triple viable probiotics minimize the postoperative occurrence of infectious complications, with possible mechanisms attributed to the maintenance of the intestinal flora and restriction of bacterial translocation from the intestine. It was representative of the enhancement of systemic/localized immunity and concurrent attenuation of systemic stress response.
机译:背景:目的是阐明口服双歧三联益生菌在大肠癌患者中的作用。方法:将60例行结直肠癌根治术的患者随机分配为3天(第-5至-3天)术前益生菌(A组,n = 30)或安慰剂(B组,n = 30)治疗。通过大肠杆菌,长双歧杆菌和肠道真菌的粪便培养评估肠道菌群的变化。血清内毒素和D-乳酸对肠屏障的功能以及外周血免疫球蛋白,白介素6和C反应蛋白的免疫和应激反应。物理,放射学和微生物学均记录了术后感染。结果:B组术前和术后存在双歧杆菌/大肠杆菌比率倒置(均P <0.05)。术后3到5天,双歧杆菌计数显着增加,而大肠杆菌计数显着下降(P <0.05),并且A组的术后双歧杆菌/大肠杆菌比率倒转直至术后3至5天。A组的内毒素水平也较低, D-乳酸,血清白细胞介素6和C反应蛋白,但血清IgG和sIgA水平高于B组。术后感染并发症的发生率分别为3.3%至6.7%和3.3%至30% A组和B组分别为10.0%和33.3%(P <0.05)。结论:术前口服双歧三联益生菌可最大程度地减少术后感染并发症的发生,其可能的机制归因于肠道菌群的维持和肠道细菌移位的限制。它代表了全身/局部免疫力的增强以及系统性应激反应的同时减弱。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号